BCAB Stock Summary and Trading Ideas (Bioatla | NASDAQ:BCAB)

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

What symbol and exchange does Bioatla shares trade?

Bioatla trades on the NASDAQ stock market under the symbol BCAB.

What is Bioatla stock price doing today?

As of December 15, 2025, BCAB stock price declined to $0.77 with 1,230,139 million shares trading.

What is Bioatla's Beta?

BCAB has a beta of 2.35, meaning it tends to be more sensitive to market movements. BCAB has a correlation of 0.11 to the broad based SPY ETF.

How much is Bioatla worth?

BCAB has a market cap of $45.41 million. This is considered a Sub-Micro Cap stock.

What is the highest and lowest price Bioatla traded in the last 3 year period?

In the last 3 years, BCAB traded as high as $9.87 and as low as $.24.

What are the top ETFs holding Bioatla?

The top ETF exchange traded funds that BCAB belongs to (by Net Assets): VTI, VXF.

Is Bioatla (BCAB) a good investment?

BCAB has underperformed the market in the last year with a price return of -46.0% while the SPY ETF gained +13.8%. BCAB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -0.3% and -14.6%, respectively, while the SPY returned +3.8% and -0.4%, respectively.

What are the support and resistance levels for Bioatla (BCAB)?

BCAB support price is $.73 and resistance is $.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCAB shares will trade within this expected range on the day.